Overview

Gender

male

Clive Dix is the Chief Executive Officer at C4X Discovery Holdings plc. since November 2015.

Clive has over thirty years' experience in the pharmaceutical and biotechnology industries. Clive was Co-Founder and Chief Executive Officer of PowderMed Limited, which was sold to Pfizer Inc. in 2006 and Co-Founder and Chief Executive Officer of Convergence Pharmaceuticals Limited, which was sold to Biogen Inc. in 2015.

Clive's other previous roles include: Senior Vice President of Research and Development at PowderJect Pharmaceuticals plc. sold to Chiron in 2003, Chairman of the UK BioIndustry Association, Chairman of the Board of Directors of Crescendo Biologicals Limited and Chairman of the Board of Directors of Auralis Limited (acquired by ViroPharma Inc).

Following post-doctoral roles and a period at Ciba-Geigy AG (now Novartis AG), Clive joined GlaxoWellcome plc. where he became UK Research Director.

Clive is currently an Executive Chairman of the Board of Directors at C4X Discovery Holdings plc., Chairman of the Board of Directors at Touchlight Genetics Limited.

Clive is a past Chairman of the Board of Directors of Calchan Ltd.

Clive earned his B.Sc. and Ph.D. degrees in Pharmacology from University of Leeds.